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Abstract 
Low concentrations of certain KATP openers have been reported to exert a moderate inhibitory 
effect on arrhythmias during post-ischaemic early myocardial reperfusion, but the accompanying 
effects on the time course of changes in action potentials in intact hearts have not yet been studied. 
We report that, in rat isolated hearts reperfusion following 10 min of regional no-flow ischaemia 
was associated with both an acute, marked, but transient, shortening of ventricular repolarisation 
(by 63%) during reperfusion, and a high incidence (90%) of ventricular tachyarrhythmias. The 
KATP opener Ro 31-6930 [2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)-pyridine 1-oxide] 
delivered prior to ischaemia at a relatively low concentration (0.5 µM), significantly reduced the 
incidence and duration of reperfusion arrhythmias, and prevented the associated acute action 
potential shortening during reperfusion, each in a glibenclamide (1 µM)-sensitive manner (P<0.05, 
n=10-15 hearts). This was associated with a moderate, and non-arrhythmogenic, action potential 
shortening during ischaemia (a potentially “cardioprotective” effect). However, these data 
highlight the potential harm these drugs may cause, since a higher concentration of Ro 31-6930 
caused marked shortening of action potentials and significant pro-arrhythmia during ischaemia. 
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1: Introduction 
 
 Cardiac adenosine triphosphate-sensitive K+ (KATP) channels, first identified in the 
sarcolemma (Noma, 1983), and more recently in the mitochondria (Inoue et al., 1991) are thought 
to remain closed under physiological conditions. It is well recognised that under certain 
pathological conditions, such as myocardial ischaemia, however, opening of sarcolemmal KATP 
channels may contribute to the shortening of action potential duration (Wilde and Janse, 1994; 
Wilde, 1997). We recently reported (Workman et al., 2000) that in the rat isolated heart, ischaemia 
in the presence (but not the absence) of pharmacological KATP activation, caused action potential 
shortening of a sufficient degree to cause ventricular tachyarrhythmias. 
 It is also recognised that KATP activation-induced action potential shortening, under certain 
conditions may help to protect the myocardium from the injury caused by excessive Ca2+ influx 
and ATP consumption [see (Grover and Garlid, 2000) for recent review]. Several studies have 
highlighted the protective effects on the myocardium of pharmacological KATP activation. In many 
cases such protection was demonstrated during post-ischaemic reperfusion. For example, KATP 
openers have been shown, during reperfusion, to improve recovery of contractile function 
(Docherty et al., 1997), to restrain the rise in the intracellular Ca2+ concentration, [Ca2+]i (Behling 
and Malone, 1995), to enhance the restoration of high energy phosphates (Tanonaka et al., 1999), 
as well as limiting the extent of myocardial infarction after reperfusion (Grover et al., 1990). The 
KATP openers also exerted effects during the preceding ischaemic episode, such as a reduction in 
[Ca2+]i (Behling and Malone, 1995) and an attenuation of ATP loss (Docherty et al., 1997). In 
other studies, such effects have been correlated with a shortening of repolarisation during 
ischaemia (Jiang et al., 1994; Tanaka et al., 1996). 
 Experimental myocardial reperfusion is invariably accompanied by a high incidence of 
ventricular tachyarrhythmias. These are often most severe after episodes of ischaemia too short to 
produce myocardial necrosis, eg: after 10 min in the rat (Hearse and Tosaki, 1988). Reperfusion 
arrhythmias are also considered to be important clinically, as highlighted by reports of patients in 
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whom serious ventricular arrhythmias occurred shortly after spontaneous relief of episodes of 
coronary spasm-induced silent ischaemia (Tzivoni et al., 1983), or in whom persistent arrhythmias 
followed successful thrombolysis (Goldberg et al., 1983), or during reperfusion of the whole heart 
after a period of surgically-induced ischaemic arrest (Rubin et al., 1985). Despite the potential 
importance of post-ischaemic reperfusion arrhythmias, the effects of pharmacological KATP 
activation on these arrhythmias have been reported infrequently, especially in the absence of 
arrhythmias during the preceding phase of ischaemia (Ferdinandy et al., 1995; Tosaki et al., 1993; 
Tanaka et al., 1996). The rat isolated perfused heart has been used extensively to study the 
pharmacological modulation of arrhythmias. With this model, Ferdinandy et al. (1995) 
demonstrated that a relatively low concentration of the KATP opener cromakalim, delivered prior to 
ischaemia, was anti-arrhythmic during reperfusion, despite the fact that higher concentrations 
caused marked pro-arrhythmia during ischaemia. These findings were consistent with earlier 
preliminary data that we presented (Workman et al., 1994) from a similar model, but using a 
different KATP opener. 
 The electrophysiological mechanisms underlying reperfusion arrhythmias are not fully 
understood, but it has been suggested that a majority may be initiated by non-reentrant 
mechanisms, such as triggered activity due to afterdepolarisations (Pogwizd and Corr, 1987), but 
are then maintained primarily by reentry, promoted in part by action potential shortening (Coronel 
et al., 1992). However, it is recognised that both mechanisms may be involved in the generation as 
well as in the maintenance of reperfusion arrhythmias (Ferrier et al., 1990; Kaplinsky et al., 1981; 
Vera et al., 1995). The time course of action potential changes that occur during post-ischaemic 
reperfusion has been studied previously in intact hearts of several species. It is generally accepted 
that there is a rapid and transient shortening of repolarisation in pigs (Coronel et al., 1992), guinea 
pigs (Culling et al., 1984; Penny and Sheridan, 1983) and rabbits (Montrucchio et al., 1989). Only 
limited data is available from the rat (Perchenet and Kreher, 1995), but in that study action 
potentials were recorded only after 1 min of reperfusion and beyond, but repolarisation also 
transiently shortened. In each of these studies, reperfusion arrhythmias only occurred if (and often 
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immediately after) the action potentials had shortened. Moreover, when reperfusion arrhythmias 
were inhibited, either by shortening the ischaemic insult (Coronel et al., 1992; Culling et al., 1984) 
or by means of ischaemic preconditioning (Coronel et al., 1992; Perchenet and Kreher, 1995), or 
with pharmacological agents, eg: with sotalol (Culling et al., 1984), there was an accompanying 
inhibition of the reperfusion-induced acute action potential shortening.  
 We therefore hypothesised that the anti-arrhythmic effect during reperfusion of KATP openers 
delivered at low concentration prior to ischaemia, as seen in the rat (Ferdinandy et al., 1995; 
Workman et al., 1994) might involve some alteration to the time course of associated changes in 
action potential repolarisation. To our knowledge, the effect of KATP modulators on the action 
potential duration during reperfusion has not been reported previously in intact hearts. Here we 
report, using rat isolated hearts, the effects of pharmacological KATP activation and blockade on 
the acute changes in repolarisation and associated arrhythmias that occur during the phase of post-
ischaemic reperfusion. 
 
 
2: Materials and methods 
 
2.1: Action potential and cardiac electrogram recording in isolated rat hearts 
 This investigation conforms with the Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986. Hearts isolated from Sprague Dawley rats (weighing approximately 500 g) 
were retrogradely perfused via the aorta at a head of pressure of either 0.66, 1.0 or 1.33 m H2O, 
with a physiological salt solution containing (mM) NaCl (136.9), glucose (11.1), MgCl2 (1.0), 
NaH2PO4 (0.3), NaHCO3 (11.9), CaCl2 (0.9) and KCl (5.0), which was bubbled with 95% O2 and 
5% CO2 (pH 7.4). Monophasic action potentials were recorded continuously from the left 
ventricular epicardial wall using a custom-built suction electrode, as described previously 
(Workman et al., 2000). The cardiac electrogram was recorded in separate hearts, using wire 
electrodes inserted into the right atrium and ventricular apex. Each preparation was continuously 
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enclosed in a thermostatically controlled jacket. The epicardial temperature, measured using a 
thermistor probe, was maintained at 36-37 oC. All voltage signals were low-pass filtered at 5 kHz, 
digitised at a minimum of 3 kHz, and stored for later analysis at high time resolution, using a 
Gould Windograph chart recorder. The action potential duration was measured at 50 and 80% 
repolarisation (APD50 and APD80, respectively). Ventricular tachycardia and ventricular 
fibrillation were categorised using the guidelines of the Lambeth Conventions (Walker et al., 
1988) and combined as ventricular tachyarrhythmia. The heart rate was calculated from the cardiac 
electrogram each minute, by measuring the number of QRS complexes which occurred during the 
preceding 20 s interval. 
 
2.2: Experimental protocols 
 All hearts were allowed to stabilise in the physiological salt solution for 10 min. When 
required, the perfusate was then switched to one containing drug(s), using independent perfusion 
lines which were selected using a mulit-way tap situated above the aorta. All drugs were 
administered prior to ischaemia only. Hearts were administered either the KATP opener Ro 31-6930 
[2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)-pyridine 1-oxide (Paciorek et al., 1990), kindly 
donated by Roche Research Centre, Herts], the KATP blocker glibenclamide (Sigma), or a 
combination of these. Ro 31-6930 is structurally related to the benzopyran KATP opener 
cromakalim, but has a much higher biological potency (Edwards et al., 1991). Its KATP opening 
activity has been reported previously in a variety of experimental models (Bott et al., 1992; Griffin 
and Scott, 1994; Finta et al., 1993), including cardiac tissue, in which 3 µM Ro 31-6930 caused 
action potential shortening, which was reversed both by 100 µM ATP and 0.3-3 µM glibenclamide 
(Bott et al., 1992). Ro 31-6930 was freshly dissolved in H2O prior to each days’ experiments, and 
used at final perfusate concentrations of between 0.05 µM and 5 µM. Glibenclamide was also 
freshly dissolved, from a stock solution previously prepared in dimethyl sulphoxide and stored at 4 
oC. The final perfusate concentration of glibenclamide was 1 µM, with 0.002% dimethyl 
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sulphoxide. Coronary flow rate was measured continuously by timed collections of coronary 
effluent. In preliminary experiments using a perfusion head of pressure of 1m, Ro 31-6930 (0.05-5 
µM) significantly increased the coronary flow rate, and maximimally at 0.05 µM, by 37% 
(P<0.05, n=10). Glibenclamide, on the other hand, reduced coronary flow at this pressure, by 39% 
(P<0.05, n=10). Therefore, in all hearts used to measure electrical activity the perfusion head was 
set to 1.0 m in the absence of drugs, 0.66 m when using Ro 31-6930, and 1.33 m with 
glibenclamide. This equalised the mean coronary flow rate between groups, and permitted the 
investigation of electrical effects of these drugs without significant interference from effects on 
coronary flow. After starting perfusion with drugs, baseline electrical recordings were made every 
minute for 15 min. A silk ligature, which had been placed around the left main coronary artery 
immediately prior to cannulation, was then tightened using a custom-made device which permitted 
rapid and remote closing and release of the ligature without disturbing temperature control. 
Electrical recordings were then made at minute intervals during a 10 min period of regional 
ischaemia. This duration was chosen since it produces a maximal incidence and duration of 
ventricular arrhythmias during post-ischaemic reperfusion in this model (Hearse and Tosaki, 
1988), and also since it does not result in myocardial necrosis. The ligature was then opened, 
allowing left ventricular reperfusion, for a further 10 min. Hearts were referred to as being “in 
ventricular tachyarrhythmia” at each data collection time point if the cardiac electrogram displayed 
any episode of ventricular tachyarrhythmia in the 1 min interval prior to that point. Hearts may 
not, therefore, have been in arrhythmia at the time of data collection. Indeed, no heart was 
arrhythmic immediately prior to reperfusion, apart from in the group treated with a high 
concentration (5 µM) of Ro 31-6930. Action potential recordings were made at 1 min intervals 
during reperfusion except for the first 2.5 min, when data was obtained every 10 s. At the end of 
each experiment, the zone of non-perfused muscle was delineated using reverse staining with 
Patent Blue V 1240 (4 g.l-1) to assess the extent and the wet weight of previously ischaemic 
muscle, and to confirm that the suction electrode had been located centrally in the non-perfused 
muscle zone. 
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2.3: Data analysis and statistics 
 All values were expressed as means±standard error (S.E.). At each data collection point the 
mean action potential duration was calculated only when a minimum of 4 action potentials per 
group of hearts could be recorded. Ventricular tachyarrhythmias often interfered with action 
potential measurement during reperfusion. Incidences of arrhythmias were compared using a χ2 
test (with Yate's Correction). All data on action potentials, arrhythmia duration, heart rate and 
coronary flow rate were first subjected to a variance ratio test. Data were then compared using 
either a Student's t test (2-tailed) or a Mann Whitney test (for non-parametric analysis), as 
appropriate. P<0.05 was considered to be statistically significant. 
 
 
3: Results 
 
3.1: Reperfusion-induced arrhythmias were attenuated by a low concentration of a KATP opener 
 Myocardial reperfusion following a 10 min period of ligation of the left main coronary artery, 
was accompanied by a high incidence of ventricular tachyarrhythmias. Fig. 1(a) shows the time 
course of changes in the incidence of such arrhythmias prior to, and during the 10 min reperfusion 
phase. In controls hearts (n=10), there were no ventricular tachyarrhythmias during ischaemia, but 
within 1 min of reperfusion, 90% of hearts were in ventricular tachyarrhythmia. Frequently this 
was initially paroxysmal. Mean onset time of the first episode of arrhythmia was 18±8 s. The 
incidence of arrhythmias then settled at 50% after min 6 of reperfusion. The total duration of 
ventricular tachyarrhythmia was 331±85 s during the first 10 min of reperfusion [Fig. 1(b)]. The 
coronary flow rate, which had fallen significantly during coronary ligation, to 71% of the pre-
ischaemic value (10.6±0.7 ml.min-1.g-1 ventricular weight) increased in all hearts within 5 s of 
opening the ligature, and was 11.6±1.0 ml.min-1.g-1 ventricular weight after 1 min of reperfusion. 
 The KATP opener, Ro 31-6930, delivered prior to ischaemia at the relatively low concentration 
of 0.5 µM, significantly reduced the incidence of ventricular tachyarrhythmias during the first 3 
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min of post-ischaemic reperfusion [Fig. 1(a)], and was not significantly arrhythmogenic during 
ischaemia. Indeed, no heart was in arrhythmia immediately prior to reperfusion in this group. The 
maximal effect of Ro 31-6930 occurred during the first minute of reperfusion, with a reduction in 
the incidence of ventricular tachyarrhythmias from 90% to 20%. However, significant inhibition of 
arrhythmias by this drug was restricted to the early phase of reperfusion. Nevertheless, Ro 31-6930 
at 0.5 µM also caused a significant reduction in the total duration of ventricular tachyarrhythmias 
during the first 10 min of reperfusion, by 64% [Fig. 1(b)]. Ro 31-6930 at the even lower 
concentration of 0.05 µM had no effect on the incidence of reperfusion arrhythmias (80%, n=10 
hearts). The effect on reperfusion arrhythmias of a higher concentration of Ro 31-6930 (5 µM), 
also delivered prior to ischaemia, could not be assessed since it was significantly pro-arrhythmic 
during ischaemia at this concentration, causing ventricular tachyarrhythmias in the 10th minute in 
9/10 hearts. Moreover, the arrhythmias persisted into reperfusion in each case. This result 
emphasises the recognised pro-arrhythmic effect during ischaemia, of KATP openers when used at 
high concentration. In the single heart that was not in ventricular tachyarrhythmia at the end of 
ischaemia with 5 µM Ro 31-6930, no arrhythmias developed during reperfusion. Ro 31-6930 had 
no significant effect on the time to onset of arrhythmias during reperfusion, at any concentration 
tested. The mean coronary flow rates prior to, during and following ischaemia were not 
significantly different from control values in any of the Ro 31-6930-treated groups (owing to the 
adjustment of perfusion pressure detailed in the Methods), and so the effects of the KATP opener on 
ventricular tachyarrhythmias were unlikely, therefore, to have been obscured or complicated by its 
vasodilator action. 
 The KATP blocker glibenclamide (1 µM) abolished the inhibitory effect of 0.5 µM Ro 31-6930 
on ventricular arrhythmias, whilst having no significant effect alone, on either the incidence or 
duration of arrhythmias prior to or during reperfusion (n=10 hearts). Fig. 1 shows that concomitant 
glibenclamide restored both the incidence of reperfusion arrhythmias (as well as the time course of 
their change), and the total duration of these arrhythmias. At the end of each experiment, the wet 
 
 
10 
weight of the region of muscle that had been made ischaemic was measured. This was found to be 
insignificantly different from the control value (0.67±0.03 g, or 52% of the total ventricular 
weight) in each of the drug-treated groups of hearts. In addition, the heart rate, at 237±14 
beats.min-1 prior to ischaemia in the control group, did not differ significantly in any of the drug-
treated groups, at any time point before or during ischaemia.  
 
3.2: Post-ischaemic reperfusion caused rapid and transient action potential shortening 
 Representative action potentials recorded from the left ventricular epicardium are shown in 
Fig. 2(a). Prior to ischaemia, the APD80 was 38 ms, and after 10 min of regional ischaemia, the 
APD80 was 39 ms (see upper traces), confirming the previously reported lack of action potential 
shortening during early ischaemia in the rat (Workman et al., 2000). In contrast, post-ischaemic 
reperfusion was accompanied by a rapid and dramatic shortening of repolarisation [Fig. 2(a), lower 
traces], with the APD80 reaching a nadir of 23 ms, in this case, after 50 s. This was often associated 
with a pronounced (near complete) phase 1 repolarisation, as illustrated in the bottom trace of Fig. 
2(a). In 2/15 hearts, however, the action potential transiently lengthened after 20 s reperfusion. An 
example, which may represent action potentials displaying subthreshold early afterdepolarisations 
is shown in the upper trace of Fig. 2(b). In this case, the APD80 after 20 s of reperfusion was 79 
ms. By 40 s of reperfusion, the APD80 had declined to 48 ms. Unfortunately, it became 
immeasurable beyond 40 s due to the onset of chaotic electrical activity characteristic of 
ventricular tachyarrhythmia ([bottom trace of Fig. 2(b)]. Chaotic electrical activity appeared (and 
therefore interfered with action potential measurement) at various times during reperfusion. Its 
appearance was not consistently preceded by either lengthening or shortening of repolarisation. 
 Fig. 3 shows the time course of changes in the mean APD80 during post-ischaemic 
reperfusion, obtained from a group of 15 hearts. The associated marked but transient action 
potential prolongation [Fig. 3(a)] which occurred early during the preceding 10 min episode of 
ischaemia, was entirely characteristic of this model and has been described in detail elsewhere 
(Workman et al., 2000). It can be seen in Fig. 3(b) that there was marked, transient and significant 
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shortening (below the pre-reperfusion value) of mean APD80 values over the first 2.5 min of 
reperfusion. This shortening was maximal between 20 and 90 s of reperfusion, in different hearts, 
reaching a nadir (with a shortening of 63% to 15±2 ms) after approximately 40 s. The time course 
of changes in mean APD50 was similar to that of APD80, but APD50-shortening did not reach 
statistical significance during reperfusion. 
 
3.3: The low dose of a KATP opener shortened action potentials during ischaemia and prevented 
further shortening during reperfusion 
 We next examined the effect on epicardial action potentials of the KATP opener Ro 31-6930 at 
the relatively low (but nevertheless, arrhythmia-inhibiting) concentration of 0.5 µM. There was no 
significant effect on repolarisation prior to ischaemia, but during ischaemia Ro 31-6930 markedly 
attenuated the initial transient action potential lengthening, as reported in detail previously 
(Workman et al., 2000). APD80 was significantly shortened to below the pre-ischaemic value at 
each time point between 4 and 10 min of ischaemia [Fig. 4(a)]. Additionally, this concentration of 
Ro 31-6930 caused significant shortening during ischaemia, of both the mean APD50 and APD80 
values, at each time point compared to the control group. For example, at min 10 of ischaemia, 
APD80 was 41.1±3.1 and 16.5±1.3 ms in the control and drug-treated groups, respectively (P<0.05, 
n=15 and 13 hearts). 
 In marked contrast to the situation in the control group (Fig. 3(b)], during post-ischaemic 
reperfusion, there was no further shortening of mean APD80 values in hearts treated with the KATP 
opener [Fig. 4(b)]. In Ro 31-6930-treated hearts, a transient lengthening in action potentials was 
observed during reperfusion (possibly indicative of action potentials displaying subthreshold early 
afterdepolarisations). As before [see Fig. 2(b)], this was seen only in two hearts. In the first, this 
occurred after 10 s of reperfusion (APD80 was 93 ms), and in the second, at both 70 and 90 s of 
reperfusion (APD80: 83 and 89 ms, respectively). Therefore, the main and usual effect of Ro 31-
6930 at 0.5 µM on action potentials during reperfusion was to prevent the normal early phase of 
shortening of repolarisation. This was associated with attenuation of the normal action potential 
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prolongation seen during the preceding episode of ischaemia. As with the earlier experiments on 
arrhythmias, the coronary flow rate in hearts treated with Ro 31-6930 was not significantly 
different from that in the control group. The ability of the KATP opener to prevent action potential 
shortening during reperfusion, therefore, was unlikely to have been obscured or complicated by its 
vasodilator action. 
 
3.4: The KATP blocker glibenclamide abolished the effects of a KATP opener on repolarisation 
during ischaemia and reperfusion 
 The KATP blocker glibenclamide at 1 µM, a concentration which was shown earlier to abolish 
the inhibitory effect of Ro 31-6930 at 0.5 µM on ventricular tachyarrhythmias (Fig. 1), abolished 
the effects of this drug on ventricular action potentials during both reperfusion and the preceding 
phase of ischaemia. This can be seen by comparing Figs. 3, 4 and 5. When delivered alone, 
glibenclamide had no effect on the action potential changes seen during ischaemia [as reported in 
detail elsewhere (Workman et al., 2000)]. Additionally, we now report that glibenclamide alone 
failed to modify the changes in repolarisation produced during reperfusion. Thus, the nadir of 
APD80-shortening during reperfusion was similar in control and glibenclamide-treated hearts, at 
15.3±1.5 and 12.2±5.3 ms, respectively (n=15 hearts each). In both groups this point was reached 
after 40 s of reperfusion. 
 Thus, glibenclamide at 1 µM, when delivered in combination with 0.5 µM Ro 31-6930 (n=15 
hearts), completely restored both transient action potential prolongation during ischaemia [as 
reported previously (Workman et al., 2000)], and the transient action potential shortening normally 
seen during reperfusion. In the drug combination-treated group, in contrast to the group given Ro 
31-6930 alone, there was marked prolongation of APD80 early during ischaemia [compare Fig. 
5(a) with Fig. 4(a)] and there was significant shortening of APD80 early during reperfusion 
[compare Fig. 5(b) with Fig. 4(b)], as seen in the unmedicated group of controls [Fig. 3(b)]. 
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4: Discussion 
 
 In this study we have demonstrated that in rat isolated hearts post-ischaemia reperfusion is 
associated with ventricular tachyarrhythmias. Using a KATP opener at a low concentration, 
delivered before ischaemia, we have also shown an inhibitory effect on these arrhythmias, during 
early reperfusion. This was closely associated with prevention by the drug of the usual acute action 
potential shortening seen early during reperfusion in this model, which in turn was associated with 
an action potential shortening effect of the drug during ischaemia. 
 The significant reduction by 0.5 µM Ro 31-6930, in both the incidence and duration of 
ventricular tachyarrhythmias during reperfusion, was unlikely to have been complicated by this 
drug’s well known vasodilator action, since coronary flow was kept similar in the control and drug 
treatment groups. The KATP blocker glibenclamide at 1 µM had no effect by itself on reperfusion 
ventricular tachyarrhythmias, and nevertheless abolished the inhibitory effect on arrhythmias 
shown by Ro 31-6930. By using glibenclamide at 1 µM we sought to minimise the risk of 
producing actions additional to KATP blockade. The ventricular A-kinase-dependent Cl- current, for 
example, is blocked with >1 µM glibenclamide (Tominaga et al., 1992). The lack of effect of 
glibenclamide on reperfusion arrhythmias is in agreement with previous studies in rats (Bernauer, 
1997; Ferdinandy et al., 1995). Nevertheless, 1 µM glibenclamide has been reported to reduce the 
duration of reperfusion ventricular fibrillation in this species (Bril et al., 1992). 
 Most KATP openers are pro-arrhythmic during ischaemia (Chi et al., 1990; Wolleben et al., 
1989). In agreement, we have previously demonstrated that Ro 31-6930 at relatively high 
concentration exerted substantial and glibenclamide-sensitive pro-arrhythmic, and action potential 
shortening, effects during ischaemia (Workman et al., 2000). A shortening of the QT interval in 
the rat was demonstrated during ischaemia with a KATP opener (Rees and Curtis, 1995b), and in 
canine epicardial tissue, shortening of repolarisation with pinacidil lead to arrhythmias with 
characteristics of reentry (Di Diego and Antzelevitch, 1993). Whilst several studies have shown 
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that KATP openers can prevent triggered activity induced by agents such as Cs+ (D'Alonzo et al., 
1993), there are few reports of any effect of KATP openers on post-ischaemic reperfusion 
arrhythmias, particularly in the absence of any pro-arrhythmic effect demonstrable during the 
ischaemic episode. Nevertheless, the KATP openers cromakalim, nicorandil and NIP-121 [((+)-7,8-
dihydro-6,6-dimethyl-7-hyroxy-8-(2-oxo-1-piperidinyl)-6H- pyrano[2,3-f]benz-2,1,3-oxadiazole)] 
have each been reported to be anti-arrhythmic during reperfusion (Ferdinandy et al., 1995; 
Kempsford and Hawgood, 1989; Tanaka et al., 1996). Moreover, in close agreement with a 
previous report on rat hearts (Ferdinandy et al., 1995), the present data show that pharmacological 
KATP activation may be both pro-arrhythmic during ischaemia and anti-arrhythmic during 
subsequent reperfusion, depending only upon the concentration of the KATP opener used. 
Furthermore, the present data highlight that whilst a KATP opener at low concentration could 
attenuate reperfusion arrhythmias without significant pro-arrhythmia during ischaemia, this should 
be interpreted cautiously due to the recognised significant risk of pro-arrhythmia with these drugs. 
 In the absence of drugs, ventricular action potentials recorded from intact hearts in the present 
study underwent a rapid, marked and significant but transient period of shortening during post-
ischaemic reperfusion. The question arises, however, of how faithfully do suction electrode-
recorded potentials reflect the time course of transmembrane action potentials recorded from the 
same region (Ino et al., 1988). Previously we demonstrated the reliability of this recording method 
in our model (Workman et al., 2000). Moreover, a period of similar reperfusion-induced early 
action potential shortening has been reported by others in the hearts of various species, including 
pig (Coronel et al., 1992), guinea pig (Culling et al., 1984; Penny and Sheridan, 1983), rabbit 
(Montrucchio et al., 1989), and rat (Perchenet and Kreher, 1995). In each of those studies, 
however, repolarisation was measured first after a full 1 min of reperfusion. That is in contrast to 
the earlier action potential measurements that were possible in the present study. Nevertheless, in a 
previous rat study (Perchenet and Kreher, 1995), in close agreement with the present findings [Fig. 
3(b)], some shortening in repolarisation was initially recorded during reperfusion (following 25 
min of ischaemia). It is noteworthy that in contrast to this early reperfusion-induced action 
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potential shortening, the rat features a marked but transient lengthening during ischaemia 
(Workman et al., 2000; Perchenet and Kreher, 1995). We recently reported (Workman et al., 2000) 
that in Langendorff-perfused rat hearts, significant flow of IKATP may not occur early on during 
regional no-flow ischaemia, as used here. Nevertheless, it is acknowledged that KATP channels 
may contribute to K+ efflux during global low-flow ischaemia in this species (Kantor et al., 1990; 
Wolleben et al., 1989). 
 The rat has been used extensively to study the effects of pharmacological KATP modulation on 
ventricular arrhythmias, and there is notable agreement between data obtained in this and other 
species. For example, during myocardial ischaemia, in dogs, rabbits, guinea-pigs and rats, KATP 
openers are generally pro-arrhythmic (Chi et al., 1990; Bellemin-Baurreau et al., 1994; Workman 
et al., 2000) whilst KATP blockers are anti-arrhythmic (Billman et al., 1993; Gwilt et al., 1992; 
Wolleben et al., 1989; Kantor et al., 1990; Rees and Curtis, 1995b). Moreover, in each of these 
species, reperfusion after only a short period of ischaemia is accompanied by both ventricular 
arrhythmias and acute action potential shortening. To our knowledge, however, the present study 
is the first to examine effects of KATP modulators on action potentials during reperfusion in the rat. 
In hearts treated with Ro 31-6930 at a concentration which inhibited reperfusion arrhythmias (0.5 
µM), there was a moderate, non-arrhythmogenic, shortening of the APD80 during ischaemia, as 
reported earlier (Workman et al., 2000). In these hearts, in marked contrast to the controls, 
however, there was no further shortening of repolarisation during reperfusion. In several previous 
studies of action potentials during post-ischaemic reperfusion, arrhythmias were only seen during 
reperfusion if (and often immediately after) repolarisation had shortened (Coronel et al., 1992; 
Culling et al., 1984; Montrucchio et al., 1989; Penny and Sheridan, 1983; Perchenet and Kreher, 
1995). Moreover, those interventions which inhibited these arrhythmias, such as reducing the 
duration of prior ischaemia (Coronel et al., 1992), preceding it with an episode of ischaemic 
preconditioning (Coronel et al., 1992; Perchenet and Kreher, 1995), or using various 
pharmacological treatments (Culling et al., 1984) all resulted in an inhibition of the acute action 
potential shortening during reperfusion. Indeed, it has already been suggested that such shortening 
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may provide the necessary substrate for reperfusion arrhythmias (Culling et al., 1984; Ferrier et al., 
1990; Coronel et al., 1992). It is conceivable, therefore, that prevention by 0.5 µM Ro 31-6930 of 
the acute shortening of repolarisation during reperfusion, may have contributed to this drug’s 
inhibitory effect on arrhythmias. Moreover, we have confirmed an involvement of KATP channel 
activation in this effect on repolarisation, as well as in the associated arrhythmias, by abolishing 
both of these effects with glibenclamide. The latter drug on its own had no effect on either 
repolarisation or ventricular arrhythmias. 
 Reperfusion-induced shortening of action potentials has previously been correlated (Coronel 
et al., 1992) with a rapid washout of extracellular K+. That ion is known to treble in concentration 
in the extracellular space during the preceding 10 min of ischaemia in the rat (Wilde et al., 1990). 
Reperfusion was reported to cause a rapid and transient undershoot in [K+]o (Coronel et al., 1992). 
Activity of the Na+,K+ pump (Na+,K+-ATPase), which is thought to play a key role in the 
development of reperfusion arrhythmias (Tani and Neely, 1991), was markedly reduced after only 
10 min of ischaemia in the rat (Avkiran et al., 1996). Reperfusion-induced [K+]o-undershoot is 
thought to result largely from recovery of Na+,K+-ATPase activity upon restoration of coronary 
flow (Coronel et al., 1992; Tani and Neely, 1991; Avkiran et al., 1996). This enzyme, whilst 
extruding the excess (Na+)i that accumulated during ischaemia, would also rapidly remove K+ 
from the extracellular space, possibly leading to a [K+]o undershoot. Indeed, in pig hearts, such an 
effect on [K+]o during reperfusion has been reported to cause hyperpolarisation, an action potential 
shortening and the attendant reentrant arrhythmogenesis (Coronel et al., 1992). Moreover, such an 
arrhythmogenesis occurred only in the presence of a reperfusion [K+]o undershoot. Interventions 
which attenuated or delayed the fall in [K+]o, also attenuated or delayed the arrhythmias. In that, as 
well as in other studies (Kaplinsky et al., 1981), the arrhythmias were deduced to have been of 
reentrant origin. That would be consistent with a shortening of the ERP, which also had been 
demonstrated previously during reperfusion (Naimi et al., 1977). 
 The ability of 0.5 µM Ro 31-6930 to shorten repolarisation during ischaemia via opening of 
sarcolemmal KATP channels without causing concurrent arrhythmias would be expected to reduce 
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the rise in [Ca2+]i during ischaemia, a potentially “cardioprotective” effect. A close correlation has 
been reported between reductions in action potential duration and [Ca2+]i by the KATP opener 
lemakalim in guinea pig ventricular myocytes (Jiang et al., 1994). Likewise, there was attenuation 
of ischaemia-induced increases in [Ca2+]i by cromakalim in intact rat hearts (Behling and Malone, 
1995). It is presently unknown whether Ro 31-6930 opens the mitochondrial KATP (mitoKATP). 
Although such an effect might reduce [Ca2+]i (Garlid, 2000; Sato and Marbán, 2000), that action 
alone would not be expected to shorten repolarisation in the way that we observed. A reduction in 
[Ca2+]i during ischaemia would be expected to attenuate the rapid rise in [Ca2+]i during 
reperfusion, as shown previously in the rat (Behling and Malone, 1995). This might inhibit 
afterdepolarisation formation during reperfusion. It might also attenuate other deleterious effects 
of [Ca2+]i overload which manifest during reperfusion. For example, a reduced rise in [Ca2+]i 
during ischaemia, would also limit Na+/Ca2+ exchange-induced (Na+)i accumulation (Tani and 
Neely, 1991), This may in turn attenuate the enhancement of Na+,K+-ATPase activity during 
reperfusion, and thus some of the acute shortening of repolarisation. This is supported by reports 
that different “cardioprotective” interventions, known to reduce [Ca2+]i during ischaemia in the rat, 
such as ischaemic preconditioning and verapamil treatment, prevented action potential shortening 
during reperfusion (Perchenet and Kreher, 1995). 
 The following limitations of the present study must be accommodated when interpreting the 
data. 1) The inhibitory effect on arrhythmias of Ro 31-6930 was mild, and with a reduction in the 
incidence of ventricular tachyarrhythmias being restricted to the early phase of reperfusion. Whilst 
an effect during this phase is recognised to be important, owing to the normally high prevalence of 
tachyarrhythmias, it must be weighed against the established pro-arrhythmic effects of higher 
concentrations of KATP openers. 2) This effect was observed at one concentration only. This may 
reflect the fact that only 3 concentrations were tested, chosen from a 100-fold range. More closely 
spaced concentrations in the vicinity of 0.5 µM would be needed before testing in-vivo. 3) This 
effect may have been due partly to IKATP flowing during reperfusion. The present study was not 
designed specifically to test this possibility, and future investigations, by perfusing hearts with Ro 
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31-6930 exclusively during the reperfusion phase are warranted. 4) Future studies should also 
utilise KATP modulators with an established selectivity for mitoKATP or sarcolemmal KATP, in order 
to investigate the relative involvement of such ion channels during reperfusion. 5) Whilst rat hearts 
share many electrophysiological similarities with those of other species, they also display some 
important differences, such as a relatively short action potential duration and a marked 
prolongation of repolarisation during ischaemia (Perchenet and Kreher, 1995; Workman et al., 
2000; Rees and Curtis, 1995a; Ponce Zumino et al., 1998). Caution should therefore be exercised 
when extrapolating the present data, particularly regarding specific drug concentrations, to those 
from other species.  
 In summary, the present study, the first to our knowledge to examine effects of KATP openers 
on acute action potential changes during reperfusion of intact hearts, suggests that, in the rat the 
inhibitory effect on arrhythmias during post-ischaemic reperfusion, obtained with a low dose of a 
KATP opener delivered prior to ischaemia, may be associated with an attenuation of acute action 
potential shortening during reperfusion. This, in turn, may be related to a shortening of 
repolarisation during the preceding ischaemic episode; a possible “cardioprotective” effect. The 
results also emphasise the potential harm (pro-arrhythmia) that ischaemia may cause with KATP 
openers, even when such drugs are anti-arrhythmic during subsequent reperfusion. 
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Figure legends 
 
Fig. 1. 
Effect of pharmacological KATP activation with a low dose of Ro 31-6930, on reperfusion-induced 
ventricular arrhythmias. 
(a) Incidence of ventricular tachyarrhythmias during left ventricular regional ischaemia and post-
ischaemic reperfusion. The incidence of reperfusion-induced arrhythmia showed a glibenclamide 
(glib)-sensitive reduction with 0.5 µM Ro 31-6930 (Ro). Values are means (n=10 hearts per 
group), *=significant difference from control value at each time point. (b) Total duration of 
ventricular tachyarrhythmia during the 10 min reperfusion phase in the same hearts. This showed a 
shortening effect on ventricular tachyarrhythmia, of KATP activation by Ro 31-6930 delivered prior 
to ischaemia. Values are means, error bars denote S.E., *=significant difference from control. 
 
Fig. 2. 
Action potential changes produced by 10 min of regional ischaemia and reperfusion. 
(a) Representative suction electrode-recorded action potential traces from the left ventricular 
epicardial wall of a single heart, with a characteristically short repolarisation phase prior to 
ischaemia and a lack of action potential shortening after 10 min of ischaemia (upper panels), but 
with a brisk shortening during reperfusion (maximal after approximately 50 s). Recording times 
are shown beneath each trace. (b) Traces from a different heart during reperfusion, illustrating the 
occasional and early presence of "long-footed" action potentials (upper panel) and the onset of 
ventricular tachyarrhythmia (lower panel). Calibration bars apply to all traces. 
 
Fig. 3. 
Time course of changes in late repolarisation during regional ischaemia and reperfusion. 
(a) Left ventricular epicardial APD80. This showed a marked but transient lengthening produced by 
10 min of left coronary artery ligation, followed by a rapid shortening during left ventricular 
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reperfusion. Values are means, error bars denote S.E. (n=15 hearts, 6-15 and 4-11 action potentials 
prior to and during reperfusion, respectively). (b) Expanded time scale to show the changes in 
action potential duration during first 3 min of post-ischaemic reperfusion. The first value (at time 
0) was obtained immediately before releasing the coronary ligature. Asterisks indicate a significant 
difference from this value for subsequent data points. 
 
Fig. 4. 
Effect of a low concentration of a KATP opener on repolarisation during ischaemia and reperfusion. 
(a) Effect of 0.5 µM Ro 31-6930 (Ro), delivered prior to ischaemia, on the time course of changes 
in APD80, showing attenuation of the lengthening during ischaemia, and a shortening after 
approximately 4 min of ischaemia. These effects were associated with an absence of further 
shortening of APD80 during reperfusion. (b) Expanded time scale to show the changes in APD80 
during first 3 min of reperfusion. There were no significant differences between the pre-
reperfusion value (time 0) and all subsequent data points. Values are means, error bars denote S.E. 
(n=13 hearts, 7-13 and 7-10 action potentials prior to and during reperfusion, respectively). 
 
Fig. 5. 
Abolition by glibenclamide of KATP opener effects during ischaemia and reperfusion. 
(a) Time course of changes in APD80. Glibenclamide (glib) at 1 µM, delivered prior to ischaemia, 
completely reversed the effects of 0.5 µM Ro 31-6930 (Ro). Thus, there was a recovery of both 
action potential prolongation during ischaemia and rapid action potential shortening during 
reperfusion. (b) Expanded scale to show the detailed time course of changes in APD80 during the 
first 3 min of reperfusion. This indicates a significant (*), marked, but transient shortening below 
the pre-reperfusion value (0 min). Values are means, error bars denote S.E. (n=15 hearts, 7-15 and 
4-13 action potentials prior to and during reperfusion, respectively). 
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